Post-NFP leverage (net-debt/EBITDA 2.1×) meets an organic-growth slowdown or a soft P&C insurance-pricing cycle
One-line thesis. Aon is one of the best businesses in the S&P 500 — a global insurance-broking oligopolist with 45% ROE, 39% adjusted operating margins and sticky recurring fee revenue — but after the ~$13B NFP acquisition inflated the FY25 headline (+9.4%), the underlying engine is a ~5% organic grower, the balance sheet carries more debt than it used to, and at ~19× forward earnings the stock already prices the quality. Great company, full price, no expert edge: Watch.
◆ Synthos call — WatchAON is a business we want at a price we don't have — it becomes a Buy below ~$330; until then, do nothing.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta (0.71) & recurring fee revenue, but net-debt/EBITDA 2.1× post-NFP and a full ~19× on mid-single-digit growth.
Growth Quality
6/10 · High
~9% forward EPS CAGR, 39% adj operating margin, 45% ROE — durable but not fast; NFP inflated FY25 headline growth.
Exponential Potential
3/10 · Low
A mature oligopoly compounder decelerating to mid-single-digit organic; $76B cap and slow-growing TAM cap any multibagger.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 15%/yrTo justify today’s $357, earnings would have to compound roughly 15% a year for 10 years (9% discount rate). Analysts forecast ~9%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Aon is a giant middleman. When a big company needs insurance — against hurricanes, lawsuits, cyber-attacks, or to fund employee health and retirement plans — Aon is the broker that shops the market, negotiates the deal, and advises on the risk. It collects fees and commissions for that, year after year, and clients rarely leave. It is an extremely profitable, boring-in-a-good-way business: for every dollar of profit shareholders put in, Aon earns about 45 cents back a year.
The catch: the stock is not cheap, and the business grows slowly — its "real" underlying growth (stripping out a big acquisition) is only about 5% a year. Last year Aon also took on a lot of debt to buy a company called NFP. So you'd be paying a premium price for steady, single-digit growth. Our verdict is Watch — a wonderful business, but at today's price there's little margin for error and no edge that says buy now rather than wait for a dip.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). The stock is stable and doesn't swing wildly (low beta), and the revenue is recurring — but the added debt and a full valuation mean a stumble would hurt.
Growth Quality 6/10 (good, not great). Superb profitability and a strong moat, but the growth is only single-digit, so it's "high-quality slow" rather than "high-quality fast."
Exponential Potential 3/10 (low). This is a mature, giant company in a slow-growing market. It compounds steadily; it will not double quickly.
The one big worry: Aon borrowed heavily for the NFP deal. If its organic growth slows or the insurance-pricing cycle turns soft while it's carrying that debt, the stock could de-rate.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = AON · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$357.46
Market cap$76B
P/E trailing16×
P/E FY26E / FY27E19× / 17×
EV / Sales5.2×
EV / EBITDA13.4×
Gross margin66.0%
Net margin22.5%
Dividend yield0.85%
Beta0.714
52-wk range$308 – $375
RSI(14)62
50 / 200-DMA$323 / $336
12-mo return+0% (SPY +21%)
Street target$395 ($355–$443)
Analyst grades19 Buy · 18 Hold · 1 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on AON · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Aon plc (NYSE: AON) is a global professional-services firm — in plain terms, the world's second-largest insurance and reinsurance broker and a major human-capital (health, retirement, wealth) advisor. Incorporated in Ireland and headquartered in Dublin, it employs ~60,000 people and serves clients in over 120 countries. CEO Greg Case has run the company since 2005. Fiscal year ends December 31.
Aon reorganized in 2024 into two reportable segments:
Risk Capital — Commercial Risk Solutions (retail brokerage, specialty) + Reinsurance Solutions (treaty and facultative reinsurance broking). This is the crown jewel: highly recurring, capital-light, oligopolistic.
Human Capital — Health Solutions (health & benefits brokerage/consulting) + Wealth Solutions (retirement, pension risk transfer, investments).
Revenue mix (FY2025, from filings):
By segment: Risk Capital $11.29B (66%) · Human Capital $5.91B (34%). Risk Capital is both larger and faster-growing.
By geography: United States $8.28B (48%) · EMEA $3.15B · UK $2.22B · Asia-Pacific $1.71B · Ireland $0.19B. Roughly half US, half international — geographically diversified but USD-reported, so FX swings the headline (a +4% FX tailwind flattered Q1'26).
The defining recent event is the ~$13B acquisition of NFP (a middle-market brokerage/benefits/wealth platform), closed in 2024, which drove FY24–FY25 headline revenue growth and the step-up in goodwill, intangibles and debt. Management has since divested NFP Wealth and Stroz Friedberg, trimming the perimeter. The strategic frame management repeats is the "Aon United" strategy executed through a "3×3 Plan."
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Aon in the Synthos knowledge base: total_claims = 0, zero net-bullish voices. No independent analyst or investor in our tracked panel has a distilled, claim-ID-reconciled view on this name. In keeping with the house standard, we will not manufacture conviction we cannot trace.
Consequently, this verdict is fundamentals- and quant-driven, cross-checked against the sell-side street view (which is context, not our anchor):
Street grades: 19 Buy · 18 Hold · 1 Sell → consensus "Buy," but notably split — nearly as many Holds as Buys, consistent with a "great business, full valuation" standoff.
Street price target: consensus $395 (high $443, low $355) — implying modest ~+11% upside from $357, itself a sign the easy money is priced in.
FMP letter rating: B+ (strong on ROE/ROA, weak on P/E and P/B — i.e. quality is high, valuation is rich).
When the KB is silent, we lean harder on the numbers and are explicit that our conviction is Low. That is the honest read here.
3. Synthos scores & the Bull / Base / Bear cases
Three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Beta 0.71 and recurring fee revenue cushion the downside, but net-debt/EBITDA 2.1× (up post-NFP) and a full ~19× forward on ~9% EPS growth leave limited margin for error. Negative tangible book (goodwill-heavy).
Growth Quality
6 · Good
45% ROE, 18% ROIC, 39% adjusted operating margin, ~66% gross margin, sticky recurring revenue — elite quality. Docked because growth is only mid-single-digit organic and FY25's +9.4% headline was NFP-inflated, not organic.
Exponential Potential
3 · Low
A mature oligopoly decelerating toward ~5% organic. $76B cap in a low-single-digit-growth end market; no acceleration, no large untapped TAM. Compounds, doesn't multiply.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. Note: forward EPS below are the adjusted (non-GAAP) figures Aon and the street quote; GAAP EPS runs lower.
Case
Key assumptions
Fair value
Bull
Organic growth reaccelerates toward high-single digits, NFP cross-sell delivers, margins expand to guidance high end, debt paid down. FY27E adj EPS beats to ~$23; quality re-rates to ~19.5×.
Organic growth slows to low-single digits, a soft P&C pricing cycle bites, NFP integration disappoints while carrying 2.1× leverage; FY27E adj EPS ~$20 and multiple de-rates to ~15×.
~$300 (−16%)
Synthos fair value = the base case, ~$375 (+5%), with the full $300–$445 span as the honest range. This anchor sits below the Street's $395 consensus — we give less benefit of the doubt to a re-rating and take the post-NFP leverage plus mid-single-digit organic reality seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures. The thin ~+5% base-case upside is exactly why the verdict is Watch, not Buy.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). AON is a high-quality compounder with essentially no exponential profile:
Forward growth: revenue CAGR FY25→FY29E ~4.8% ($17.18B → $20.72B avg est); adjusted EPS CAGR FY26E→FY29E ~9% ($19.13 → $24.80 avg est), with the gap over revenue driven by margin expansion and buybacks, not volume.
Acceleration (the 2nd derivative) is negative: FY25 headline +9.4% was NFP-acquisition-inflated; underlying organic growth was ~5% in FY25 and ran 5% in Q1'26 (Commercial Risk +7%, Reinsurance +4%, Health +4%, Wealth +1%). Estimates then step down to ~4–5% revenue growth per year through 2029. This is a decelerating grower, not an accelerating one.
Room to run: the global insurance-broking / risk-advisory market is enormous but grows in the low-single digits (roughly with GDP + insurance-pricing cycle). At $76B market cap in a slow-growing, share-stable oligopoly, there is no large untapped TAM to inflect against. A 5× from here is not a credible base or even bull outcome.
Reinvestment runway: capital-light (capex ~1.6% of revenue), so incremental capital goes to M&A and buybacks — good for per-share compounding, but not a growth-acceleration engine.
Exponential Potential: Low (3/10). Own AON, if at all, for steady mid-to-high-single-digit earnings compounding plus buybacks, never for a fast multibagger. Per our flagship philosophy we prize forward next-exponentials over trailing compounders; AON is a trailing compounder and scores accordingly.
Revenue: FY25 $17.18B, +9.4% (FY24 $15.70B, +17.4% on FY23 $13.38B). But the FY24–25 jump is heavily NFP-driven; organic growth is ~5%. Five-year trend: $11.07B (FY20) → $17.18B (FY25).
Quarterly cadence (seasonal, Q1/Q4 heavy): Q1'25 $4.73B → Q2 $4.16B → Q3 $4.00B → Q4 $4.30B → Q1'26 $5.03B (+6% YoY, of which +5% organic and +4% FX, −3% divestitures).
Margins: gross 66.0% TTM, EBITDA 38.7% TTM, net 22.5% TTM. Management's adjusted operating margin was 39.1% in Q1'26 (+70 bps YoY) — the metric they guide to. Best-in-class for a services firm.
Earnings: GAAP net income $3.70B FY25 (EPS diluted $17.02, up from $12.49 FY24). Q1'26 GAAP diluted EPS $5.63 (+27% YoY), adjusted EPS $6.48 (+14%).
Returns on capital:ROE 45%, ROIC 13.5%, ROCE 17.9% — elite. (ROE is flattered by a thin, goodwill-heavy equity base; tangible book is negative.)
Cash flow: operating CF $3.48B, capex −$0.26B, FCF $3.22B FY25 (FCF margin ~19%). Q1'26 FCF jumped 332% YoY to $363M on lower cash taxes. High cash conversion is a genuine strength.
Balance sheet: total debt $16.5B, net debt $15.3B, net-debt/EBITDA ~2.1× — elevated post-NFP (was ~1.7× pre-deal). Interest coverage ~6×. Investment-grade but no longer under-levered. Goodwill + intangibles $21.5B vs $9.4B total equity → negative tangible equity, the structural cost of a roll-up model.
6. Valuation — priced in or room?
AON is not cheap, but not egregious: 19.5× trailing GAAP EPS, ~18.7× FY26E adjusted, ~16.7× FY27E adjusted, EV/EBITDA 13.4×, EV/S 5.2×, FCF yield ~4.6%. For a 45%-ROE, 39%-margin oligopolist those multiples are defensible — the question is whether ~9% forward EPS growth justifies paying up.
The PEG on trailing earnings looks benign (~0.35), but on forward growth the picture is a full ~1.7× forward PEG (FMP) — you're paying roughly 19× for high-single-digit growth. That is priced-for-quality, not priced-for-upside.
A dividend + buyback story: ~0.85% yield, ~16% payout, sixth consecutive double-digit dividend raise (10% in April 2026), plus ~$1B/yr buybacks shrinking the share count (215.4M diluted in Q1'26 vs 217.9M a year prior).
Street targets (context): consensus $395, high $443, low $355. Our ~$375 base-case FV is below consensus — we don't underwrite a re-rating and we weight the 2.1× leverage and decelerating organic more heavily.
Read: a quality-compounder-at-a-full-price. Not a value entry; a name to accumulate on weakness (toward the high-$200s / low-$300s) rather than chase at $357.
7. Technicals (from the tech block)
Trend: mildly up. $357 sits above the 50-DMA ($322.6) and 200-DMA ($336.1), with the 50 back above the 200 — constructive posture. MACD +4.6 (positive).
Location:−4.7% off the 52-week high ($375.3), +16% off the 52-week low ($308.3); max drawdown from peak was −12.7% — a low-volatility name that never fell far.
Momentum: RSI(14) 62 — firm but not overbought (<70).
Relative strength (the tell): AON is a laggard — +0.1% 12-mo vs SPY +20.6% and QQQ +30.3%; +11.2% 3-mo (vs SPY +13.7%, QQQ +22.0%). It has badly trailed the market over the past year, consistent with a defensive name that de-rated while risk assets ran.
Read: technicals are neutral-to-mildly-positive on an absolute basis but show persistent relative underperformance. No urgency to buy; the chart neither confirms nor contradicts the "wait for a better price" stance.
8. Moat & competitive position
Aon's moat is real and structural: (1) oligopoly — global commercial insurance and reinsurance broking is dominated by a handful of players (Aon, Marsh McLennan, Gallagher, WTW), with high barriers from scale, data, and trusted relationships; (2) switching costs — clients embed brokers into their risk, benefits and reinsurance programs, driving high retention and recurring revenue; (3) data and analytics scale — Aon leverages proprietary data across placements, a genuine edge in specialty and reinsurance. Capital-light economics (ROIC 13.5%, capex ~1.6% of sales) round out a durable franchise.
The counterweights: growth is tied to the insurance-pricing cycle (soft markets pressure commissions) and low-single-digit end-market volume; and the moat does not translate into fast growth — it protects a mature annuity.
Peer set (market cap): the truest comps are Marsh & McLennan ($90B) and Arthur J. Gallagher ($65B) — the direct broker peers; MMC is larger and higher-multiple, AJG the closest growth comp. The FMP-supplied "peer" list also includes unrelated financials (Apollo, BNY Mellon, PNC, ING, Nu Holdings, Mizuho, Scotiabank, CIBC) that are not true operating comparables and should be ignored for valuation. Against MMC and AJG, Aon trades at a modest discount, reflecting its higher leverage and slightly slower organic profile.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — Q1'26 returned $662M via dividends + buybacks; 10% dividend increase in April 2026 (sixth straight double-digit raise); ~$0.8B buyback authorization remaining at quarter-end. The offsetting concern is that the NFP deal levered the balance sheet to ~2.1×, and post-deal divestitures (NFP Wealth, Stroz Friedberg) suggest some portfolio pruning.
Insider activity: the sampled window (filings 2026-06-29) is entirely routine director equity awards (A-Award at $0.01, i.e. grants) with small tax-withholding dispositions (F-InKind at $315.95) — no discretionary open-market selling or buying signal either way.
Management's own guidance (half-weighted — their self-interested words). Per Aon's SEC 8-K/Q1'26 earnings release (2026-05-01), management reaffirmed 2026 guidance of: "mid-single-digit or greater organic revenue growth, 70–80 basis points of adjusted operating margin expansion, strong adjusted EPS growth, and double-digit free cash flow growth." They also flagged an expected ~$0.44/share favorable FX tailwind to full-year 2026 adjusted EPS at then-current rates. Treat as management's book: it confirms the mid-single-digit organic reality and a margin-expansion + FCF story, but it is not an outside opinion.
10. Catalysts & what to watch
Next earnings: 2026-07-24 (Q2'26; Street EPS est $3.77, revenue est ~$4.29B). The key lines: organic revenue growth (is it holding ~5%?) and adjusted operating-margin expansion (on track for the 70–80 bps guide?).
NFP integration & cross-sell: evidence the ~$13B deal is delivering revenue synergies, not just headline scale.
Deleveraging: net-debt/EBITDA trending back below ~2× would de-risk the story.
Insurance-pricing cycle: commercial P&C and reinsurance rate trends — a soft market pressures organic growth.
FX: roughly half of revenue is non-US; the dollar's direction swings reported EPS (a ~$0.44 FY26 tailwind flagged by management).
Thesis tripwires (what would change the call): organic growth falling below ~4% for two quarters; adjusted operating margin failing to expand; leverage staying above ~2.2×; or a soft-market inflection in P&C pricing. Conversely, a pullback toward the high-$200s with organic holding ~5% would move this toward Buy — Tactical.
11. Key risks
Valuation / no margin of safety: ~19× forward on ~9% EPS growth; a growth or margin miss de-rates the stock (our bear −16%).
Post-NFP leverage (structural): net-debt/EBITDA 2.1× and negative tangible equity mean less balance-sheet cushion than historically; a downturn plus debt is the core risk.
Organic-growth deceleration: mid-single-digit and estimated to stay there; the NFP-inflated headline masks a slow underlying engine.
Cyclicality: commissions are geared to the insurance-pricing cycle; a soft market pressures the top line.
FX translation: ~half of revenue is non-USD; a stronger dollar reverses the current tailwind.
No expert edge: zero Synthos KB coverage — the thesis rests entirely on fundamentals/quant, so we carry lower conviction than on covered names.
12. Verdict, position sizing & monitoring
Watch. Aon is genuinely one of the highest-quality businesses in the index — 45% ROE, 39% adjusted operating margin, sticky recurring revenue, an oligopoly moat, and disciplined capital returns. But three things keep it off the buy list today: (1) the FY25 headline growth was NFP-inflated, with true organic running ~5% and decelerating; (2) the NFP deal pushed leverage to 2.1× with negative tangible equity; and (3) at ~19× forward with a ~$375 base-case fair value (+5%)below the $395 street consensus, there is little margin for error and no expert edge to lean on (zero KB coverage).
Sizing: if held, treat as a low-beta defensive ballast, ~2–3% — a compounder to own on weakness, not to chase here. Prefer to accumulate toward the high-$200s / low-$300s.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A pullback with organic holding ~5% flips this to Buy — Tactical; a leverage or organic deterioration flips it toward Avoid. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $357.46.
Single biggest risk: post-NFP leverage colliding with an organic-growth or P&C-pricing slowdown.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — Aon has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no conviction is fabricated (there are no claim_ids to cite because none exist).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release dated 2026-05-01. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates; forward EPS are the adjusted (non-GAAP) figures the street quotes.
Management caveat: Aon's reaffirmed 2026 guidance is management's own, self-interested words, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").